Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 5 Jun 2015

NuCana’s potent anti-cancer completed Phase I/II

Good news just keeps on coming from ASCO Annual Meeting. Edinburgh-based NuCana presented in two abstracts the last data from Acelarin, the company’s first anti-cancer agent, produced on its ProTide developing platform. ProTides are NuCana’s new class of anti-cancer agents, which are specifically designed to overcome key cancer resistance mechanisms that severely limit the action […]

June 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Jun 2015

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 5 Jun 2015

Novartis declines Gamida’s buyout deal for the second time

Novartis has rejected the Israeli biotech Gamida Cell… again. The Big Pharma has decided not to carry out its option on the Israel-based company. The transaction would have meant a €535.5M deal but it won’t happen, despite Gamida having fulfilled the milestones of the bilateral agreement. Novartis, however, will maintain their collaboration. It is the second time […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data have shown that there is nothing to worry about. MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target […]

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

[Update] AstraZeneca to buy a CAR-T expert?

[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca’s CEO Pascal Soriot. The CEO was not talking about the specific acquisition of Juno Therapeutics but about a potential acquisition of a CAR-T expert. Juno’s shares rose as much as 15.8 % just after the rumor was released by Bloomerg. Here is the first version […]

June 4, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Poor topline results for NeuroVive’s CicloMulsion Phase III

Phase III is a critical step in a drug development process. NeuroVive Pharmaceutical has learned this the hard way. The Swedish company reported unsatisfactory results of CicloMulsion’s phase III clinical trial in patients having gone through a specific type of heart attack known as STEMI (ST-segment elevation acute myocardial infarction). The disappointing topline results are expected to […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform. Vaxiclase is a technology platform that can be used with many antigens in several […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Immuno-oncology has gone from a competition to a battlefield. Bristol-Meyer Squibb launched a lawsuit against David Berman, a former researcher that abruptly quit last month after 10 years working for the company’s cancer R&D division. Berman, with his deep knowledge about BMS’s immune-oncology research, headed to AstraZeneca, BMS’ principal opponent. Game on. In this competitive […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

ASCO Annual Meeting keeps bringing positive results of European companies that cross the ocean to present their clinical trial outcomes. DNA Therapeutics, the French biopharma, presented the results of the first-in-man phase I/IIa trial of DT01 in patients with cutaneous metastatic melanoma. Cancer cells can easily repair themselves after damage incurred in their DNA from […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

Eisai receives Europe’s OK for its Thyroid Cancer treatment

Lenvatinib, Eisai’s treatment of thyroid cancer, has received the marketing authorization of the European Commission. The Japanese company is increasing its European presence with Lenvatinib, an orally administered molecular-targeted agent. Lenvatinib, commercially sold under the name Lenvima, is a designated orphan drug in Japan, the United States and in Europe for the treatment of people with […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Private investors have finally backed Mapi Pharma’s project with €9.1M. Shavit Capital has led the Series A financing round to support the company’s clinical development plans. The cash raised is sufficient to advance the company’s lead product Glatiramer Acetate (GA) Depot to its Phase III. The Israeli company has a bitter record of failed NASDAQ […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

NuCana’s potent anti-cancer completed Phase I/II

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Novartis declines Gamida’s buyout deal for the second time

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

[Update] AstraZeneca to buy a CAR-T expert?

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Poor topline results for NeuroVive’s CicloMulsion Phase III

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

Eisai receives Europe’s OK for its Thyroid Cancer treatment

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Subscribe to our newsletter to get the latest biotech news!